{
    "2020-10-30": [
        [
            {
                "time": "",
                "original_text": "智飞生物新冠疫苗关键数据出炉 具备安全性可开展III期临床实验",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "新冠疫苗",
                        "III期临床",
                        "安全性"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医疗健康-基金3Q分析：三季度医药板块配置比例同比上升 环比下降",
                "features": {
                    "keywords": [
                        "医疗健康",
                        "基金",
                        "医药板块",
                        "配置比例",
                        "同比上升",
                        "环比下降"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物重组新冠疫苗三期筹备中，一二期未发现严重不良事件",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "重组新冠疫苗",
                        "III期筹备",
                        "严重不良事件"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "中国研发新冠病毒重组亚单位疫苗完成二期临床",
                "features": {
                    "keywords": [
                        "中国",
                        "新冠疫苗",
                        "重组亚单位",
                        "二期临床"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物新冠疫苗将进三期临床试验 ST电能前三季扭亏为盈",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "新冠疫苗",
                        "III期临床",
                        "ST电能",
                        "扭亏为盈"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "能源"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "人民金融·创新药指数涨0.9% 智飞生物新冠疫苗获进展",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "智飞生物",
                        "新冠疫苗",
                        "进展"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物合作研发新冠疫苗将进入Ⅲ期临床试验",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "新冠疫苗",
                        "III期临床"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}